Progesterone Vaginal: Uses, Doses, and How It Compares to Other HRT Options

What Vaginal Progesterone Actually Is

Vaginal progesterone is micronized natural progesterone formulated for intravaginal use, either as a bioadhesive gel, a suppository, or a capsule inserted vaginally. The two most recognized branded forms are Crinone (a polycarbophil-based gel) and Endometrin (a compressed insert). Compounding pharmacies also produce capsules containing 100 mg or 200 mg of micronized progesterone that women insert vaginally rather than swallowing, which changes the pharmacokinetic profile considerably.

The vaginal route takes advantage of what researchers call the "first-uterine-pass effect," a phenomenon in which progesterone absorbed through the vaginal epithelium concentrates in uterine tissue before reaching the general circulation. A 2005 pharmacokinetic study published in Fertility and Sterility confirmed that vaginal progesterone produces uterine tissue concentrations three to ten times higher than the corresponding serum levels would predict, explaining why relatively modest doses can protect the endometrium [1]. This is meaningfully different from oral micronized progesterone, which undergoes extensive hepatic metabolism and produces sedating neurosteroid metabolites (allopregnanolone) that many women notice as next-morning grogginess.

Women who find oral Prometrium causes unacceptable drowsiness are often switched to vaginal administration of the same micronized progesterone capsule. The dose is not automatically equivalent, but most clinicians use 100 mg vaginally as roughly comparable in endometrial effect to 200 mg orally, though formal bioequivalence data remain limited.

Why the Uterus Changes Everything in HRT

Estrogen stimulates endometrial cell proliferation. Without progestogen opposition, that stimulation can progress to simple hyperplasia, complex hyperplasia, and, in some cases, endometrial carcinoma. The risk is not hypothetical. The landmark PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=596) showed that 62% of women taking unopposed conjugated equine estrogen for three years developed some degree of endometrial hyperplasia, compared with 1% of those receiving combined estrogen-progestogen therapy [2].

Any woman with a uterus who is prescribed systemic estradiol, whether as a daily oral tablet, a twice-weekly patch, a once-daily thigh gel such as Divigel, or a daily arm spray such as Evamist, must receive a progestogen in parallel. Vaginal progesterone is one of several acceptable choices; synthetic progestins such as medroxyprogesterone acetate or norethindrone acetate are others. The clinical decision between them involves tolerability, cardiovascular risk profile, and patient preference.

The 2022 Menopause Society (formerly NAMS) position statement states: "Micronized progesterone is the preferred progestogen for women in whom progestogen is indicated because of its more favorable metabolic and cardiovascular profile compared with synthetic progestins" [3]. Vaginal delivery of micronized progesterone is one practical way to obtain that profile while minimizing sedation.

Crinone, Endometrin, and Compounded Options: What Each Offers

Crinone 4% and 8% gels use a polycarbophil base that adheres to vaginal mucosa and releases progesterone over roughly 24 to 72 hours. The 8% formulation (90 mg per application) is FDA-approved for progesterone supplementation in assisted reproductive technology (ART) cycles and for luteal phase support. Its use in postmenopausal HRT is off-label, though widely practiced. The 4% gel is FDA-approved for infertility treatment in premenopausal women with inadequate luteal phase progesterone.

Endometrin is a 100 mg compressed vaginal insert approved for ART luteal support. It dissolves within 30 to 60 minutes and is typically used twice or three times daily in IVF protocols, a frequency that would be burdensome in long-term HRT.

Compounded vaginal progesterone capsules, usually 100 mg or 200 mg, are the most common form used in HRT practice. The capsule is placed in the vagina at bedtime, the gelatin shell dissolves, and the micronized powder disperses across the mucosa. Because these are compounded rather than FDA-approved in this specific formulation, quality depends on the compounding pharmacy's adherence to USP standards. The FDA's guidance on pharmacy compounding notes that compounded products lack the same approval standards as manufactured drugs, which means women should use accredited 503B outsourcing facilities or state-licensed 503A pharmacies when possible [4].

A practical selection framework used by the HealthRX clinical team categorizes vaginal progesterone candidates into three groups: (1) women who cannot tolerate oral progesterone due to sedation and who have no contraindication to vaginal use; (2) women seeking lower systemic progestogen exposure to reduce breast tissue stimulation, as suggested by the E3N cohort data discussed below; and (3) women undergoing fertility preservation or ART who need high endometrial concentrations of progesterone for implantation support. The dose and frequency differ across these three groups, and no single protocol fits all.

Progesterone and Breast Cancer Risk: What the Data Show

The choice between synthetic progestins and micronized progesterone matters because observational data consistently suggest they carry different breast cancer signals. The French E3N cohort (N=80,377 postmenopausal women, median follow-up 8.1 years) found that women using transdermal estradiol combined with micronized progesterone had no statistically significant increase in breast cancer risk (relative risk 1.00 to 95% CI 0.83 to 1.22), while those using transdermal estradiol with synthetic progestins had a relative risk of 1.69 (95% CI 1.50 to 1.91) [5]. These are observational findings and cannot establish causation, but they have influenced guideline language and prescriber behavior in Europe and increasingly in North America.

Vaginal progesterone produces lower serum concentrations than oral progesterone at comparable endometrial-protective doses. Whether that translates into even lower breast tissue exposure is biologically plausible but not yet confirmed in prospective trials.

Estradiol Delivery Options and Which Pairings Work With Vaginal Progesterone

Vaginal progesterone is pharmacologically compatible with every estradiol delivery route. Choosing an estradiol formulation is a separate clinical decision that depends on cardiovascular history, preference, and skin tolerance.

Oral Estradiol

Oral estradiol (17-beta estradiol tablets, 0.5 mg to 2 mg daily) undergoes first-pass hepatic metabolism, which raises sex hormone-binding globulin (SHBG) and, at higher doses, triglycerides and C-reactive protein. A 2010 randomized trial in Arteriosclerosis, Thrombosis, and Vascular Biology (ESTAL trial, N=321) showed oral estradiol significantly increased SHBG and triglycerides compared with transdermal estradiol at equivalent clinical doses [6]. Women with hypertriglyceridemia or a history of venous thromboembolism are generally steered toward transdermal routes. Oral estradiol paired with vaginal progesterone is a common, cost-accessible combination; generic 1 mg estradiol tablets are widely available below $20 per month.

Estradiol Patch

Twice-weekly transdermal patches (available from 0.025 mg to 0.1 mg/day dose rates) bypass hepatic first-pass metabolism entirely. The ESTHER study (N=881) demonstrated that transdermal estradiol did not increase venous thromboembolism risk, with an odds ratio of 0.9 (95% CI 0.45 to 1.78), in contrast to oral estradiol, which carried an odds ratio of 3.5 (95% CI 1.8 to 6.8) [7]. Women with a prior VTE or who are obese may particularly benefit from the patch. Common brands include Vivelle-Dot and generic ethinyl estradiol matrix patches. The patch is worn on the lower abdomen or buttock and changed on a fixed schedule; adhesion can be a practical issue in hot climates or for active women.

Estradiol Gel (Divigel)

Divigel 0.1% estradiol gel is applied to one thigh daily in a single-unit foil packet. Dose options are 0.25 g (0.25 mg estradiol), 0.5 g (0.5 mg), and 1.0 g (1.0 mg). A phase III trial supporting the Divigel FDA approval (N=495 to 12 weeks) showed a reduction in moderate-to-severe hot flashes of approximately 74% versus 51% placebo at the 0.1% 1.0 g dose (P<0.001) [8]. Divigel is rubbed into the upper thigh skin until dry; women should wash hands after application and avoid contact transfer to partners or children, as accidental estrogen exposure is a real concern documented in FDA safety communications [9].

Estradiol Spray (Evamist)

Evamist delivers 1.53 mg estradiol per spray applied to the inner forearm. One to three sprays daily are used depending on symptom response. The spray dries quickly (under two minutes) and leaves no residue detectable to the touch after drying. Transfer risk is lower than with gels because of the small application area and faster evaporation, but the FDA still recommends covering the area with clothing after the spray dries if close skin contact with children is expected [9]. A 12-week randomized controlled trial (N=454) showed Evamist 1 spray/day reduced weekly moderate-to-severe hot flash frequency by 46% versus 22% placebo (P<0.001) [10].

Dosing Vaginal Progesterone for HRT Endometrial Protection

Dosing schemas for vaginal progesterone in HRT endometrial protection are not as standardized as for oral Prometrium, partly because the compounded route lacks FDA approval for this indication. The approaches used in clinical practice fall into two broad categories.

Continuous combined: 100 mg vaginal micronized progesterone nightly alongside daily estradiol. This mirrors the oral Prometrium 100 mg continuous regimen studied in the KEEPS trial (Kronos Early Estrogen Prevention Study, N=727), though KEEPS used oral administration [11]. Continuous regimens aim for amenorrhea after the first three to six months of use and are preferred by most postmenopausal women who no longer want any bleeding.

Sequential (cyclic): 200 mg vaginally for 12 to 14 days per calendar month, producing a scheduled withdrawal bleed. This approach is generally reserved for perimenopausal women who are still cycling or who prefer a bleed as a reassurance signal that the uterus is being protected.

Endometrial surveillance with transvaginal ultrasound (endometrial stripe <4 mm on a continuous regimen is generally reassuring) or biopsy may be warranted if breakthrough bleeding occurs. The American College of Obstetricians and Gynecologists recommends evaluation of any unscheduled bleeding in a postmenopausal woman on HRT, regardless of progestogen route [12].

Side Effects and Contraindications

Vaginal progesterone is well tolerated by most women. The most common local effects are vaginal discharge from the gel base (particularly with Crinone, which can accumulate as a white residue), mild irritation, and occasional bloating. Systemic progestogenic side effects, including mood changes, breast tenderness, and fluid retention, are less frequent than with oral progesterone at comparable endometrial doses, consistent with the lower serum levels achieved.

Absolute contraindications include undiagnosed abnormal uterine bleeding, known or suspected progesterone-sensitive cancer, active thromboembolic disease, and known hypersensitivity to progesterone or the vehicle components (peanut oil is used in some formulations; women with severe peanut allergy should confirm the excipient list). Women who have had a hysterectomy do not need any progestogen and should not receive one routinely, as unnecessary progestogen adds risk without benefit.

Monitoring and When to Reassess

The Menopause Society recommends annual HRT review for any woman on hormone therapy [3]. At each review, the clinician should confirm that the progestogen dose and route remain adequate for endometrial protection, that the estradiol dose is still the lowest effective dose for symptom control, and that the benefit-risk balance continues to favor treatment. Serum progesterone levels drawn on the day after vaginal administration are not a reliable proxy for endometrial exposure because of the first-uterine-pass effect; a low serum level does not mean the uterus is unprotected.

Women who report persistent breakthrough bleeding on a continuous combined regimen should undergo transvaginal ultrasound as a first step, with biopsy if the stripe measures 4 mm or greater. The threshold for investigation is lower than in untreated women because any bleeding in a woman on continuous progestogen is technically unexpected and warrants explanation.

Comparing Vaginal Progesterone to Synthetic Progestins

Medroxyprogesterone acetate (MPA), norethindrone acetate (NETA), and levonorgestrel (used in the Mirena IUD for local endometrial protection) are the main synthetic alternatives. MPA was the progestogen used in the Women's Health Initiative (WHI, N=16,608), which identified the increased breast cancer signal in the combination arm after a mean of 5.6 years [13]. That signal has not been replicated in studies using micronized progesterone, though direct randomized head-to-head trials of sufficient size and duration do not yet exist.

The Mirena IUD offers another approach: it releases 20 mcg levonorgestrel per day locally, protecting the endometrium while minimizing systemic progestogen exposure. For women who cannot tolerate any vaginal administration (due to prolapse, vaginismus, or preference), the Mirena is a viable option, and ACOG endorses its use as endometrial protection in HRT [12].

Vaginal progesterone sits in a middle position: more systemic than Mirena, less systemic than oral Prometrium, with a tolerability advantage over MPA for many women.

Practical Tips for Starting Vaginal Progesterone

Insert the capsule or gel applicator at bedtime. The horizontal position reduces leakage and allows more contact time with vaginal mucosa. With compounded capsules, using a reusable applicator (similar to a tampon applicator) improves placement and reduces mess. With Crinone gel, the prefilled applicator is single-use; women sometimes notice accumulated white residue after several days of use, which is the gel carrier and not pathologic discharge.

Avoid inserting vaginal progesterone within two hours of vaginal estrogen creams or rings, as the vehicles may interact and reduce absorption of both. Spacing the two by at least two hours is standard clinical advice, though formal pharmacokinetic studies on this interaction are limited.

Store compounded capsules in a cool, dry location away from direct light. Heat degrades micronized progesterone faster than most synthetic progestins, and a compromised product may provide inadequate endometrial protection even when the dose appears correct on the label.